Anxo Pharmaceutical Co Ltd is a Taiwan-based company engaged in the research and development, manufacturing and sales of pharmaceuticals, technical services and original equipment manufacturer (OEM) services. The Company's main products include oral preparations (tablets, capsules, liquids, inhalation preparations), injections and topical preparations for the treatment of cardiovascular, central nervous system, endocrine, antimicrobial, urinary tract and blood and kidney diseases. The Company mainly operates in the Taiwan market as well as overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-06-22	17.00 NT$	0.00%	86,838
26-06-18	17.00 NT$	+1.80%	41,410
26-06-17	16.70 NT$	-1.18%	48,489
26-06-16	16.90 NT$	+0.30%	37,269

End-of-day quote Taipei Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Taipei Exchange Other stock markets 2026-06-22			5-day change	1st Jan Change
17.00 ^TWD	0.00%		+0.89%	-9.33%

Apr. 29	Anxo Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25-08-13	Anxo Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI

Market Cap	950M 30.01M 26.22M 24.25M 22.64M 42.5M 2.84B 42.81M 288M 112M 1.39B 113M 110M 4.84B	P/E 2024	-23.3x	P/E 2025	-30.7x
Enterprise Value	1.32B 41.75M 36.48M 33.74M 31.49M 59.12M 3.95B 59.56M 401M 156M 1.94B 157M 153M 6.74B	EV / Sales 2024	1.9x	EV / Sales 2025	1.68x
Free-Float	98.34%	Yield 2024 *	-	Yield 2025	-

Apr. 29	Anxo Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25-08-13	Anxo Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-04-16	Anxo Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-08-14	Anxo Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-04-30	Anxo Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
23-08-12	Anxo Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
23-04-27	Anxo Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
22-08-12	Anxo Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	CI
22-04-27	Anxo Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
21-08-12	Anxo Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	CI
21-04-22	Anxo Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	CI
20-08-13	Anxo Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	CI
20-04-28	Anxo Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019	CI

1 week	+0.89%
Current month	-3.95%
1 month	-6.85%
3 months	-15.42%
6 months	-13.27%
Current year	-9.33%

Anxo Pharmaceutical Co., Ltd. Stock

Stocks

6677

TW0006677008

Pharmaceuticals

Valuation: Anxo Pharmaceutical Co., Ltd.

Chart: Anxo Pharmaceutical Co., Ltd.

Latest news : Anxo Pharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Anxo Pharmaceutical Co., Ltd.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	16.4	17.2
1 month	16.35	18.25
Current year	16.35	21.85
1 year	16.35	30.5
3 years	15.75	77.2
5 years	15.75	77.2
10 years	15.75	77.2

Manager	Title	Age	Since
Lin Chuan Yan CEO	Chief Executive Officer	-	2020-12-31
Chih Hsien Chen DFI	Director of Finance/CFO	-	2015-09-30
Te Chu Sun IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Chung Cheng Chen BRD	Director/Board Member	-	2018-05-22
Kuang Yang Hsu BRD	Director/Board Member	-	2018-05-22
Chien Chih Wang CHM	Chairman	-	2012-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ANXO PHARMACEUTICAL CO., LTD.	0.00%	+0.89%	-1.73%	-74.70%	30.01M
ELI LILLY AND COMPANY	+0.32%	-2.41%	+44.49%	+140.80%	983B
JOHNSON & JOHNSON	+1.27%	-1.85%	+54.41%	+39.65%	557B
ABBVIE INC.	+6.25%	+3.80%	+24.13%	+67.39%	406B
ROCHE HOLDING AG	+0.25%	-1.93%	+23.33%	+16.35%	314B
ASTRAZENECA PLC	+0.42%	+0.68%	+27.89%	+14.57%	273B
NOVARTIS AG	+1.67%	+0.05%	+26.76%	+33.56%	272B
NOVO NORDISK A/S	+2.39%	+5.02%	-36.96%	-44.76%	203B
AMGEN INC.	+2.11%	-1.66%	+19.14%	+50.10%	186B
GILEAD SCIENCES, INC.	+0.90%	+0.46%	+15.09%	+59.86%	155B
Average	+1.56%	-0.74%	+19.65%	+30.28%	335.04B
Weighted average by Cap.	+1.56%	-2.22%	+31.18%	+64.35%

	2024	2025
Net sales	895M 28.29M 24.72M 22.86M 21.34M 40.06M 2.67B 40.35M 272M 106M 1.31B 106M 104M 4.57B	843M 26.64M 23.28M 21.53M 20.1M 37.73M 2.52B 38.01M 256M 99.56M 1.24B 100M 97.85M 4.3B
Net income	-57.21M -1.81M -1.58M -1.46M -1.36M -2.56M -171M -2.58M -17.36M -6.75M -83.97M -6.79M -6.64M -292M	-34.13M -1.08M -942K -872K -814K -1.53M -102M -1.54M -10.36M -4.03M -50.1M -4.05M -3.96M -174M
Net Debt	365M 11.55M 10.09M 9.33M 8.71M 16.35M 1.09B 16.47M 111M 43.15M 536M 43.35M 42.41M 1.86B	372M 11.74M 10.26M 9.49M 8.86M 16.63M 1.11B 16.75M 113M 43.87M 545M 44.08M 43.12M 1.89B